Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 13 studies | 19% ± 4% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 21% ± 3% | |
ciliated cell | 6 studies | 32% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 20% ± 4% | |
epithelial cell | 5 studies | 34% ± 14% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 17% ± 2% | |
endothelial cell | 4 studies | 22% ± 7% | |
fibroblast | 4 studies | 23% ± 6% | |
CD8-positive, alpha-beta T cell | 4 studies | 17% ± 1% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
hematopoietic precursor cell | 3 studies | 20% ± 4% | |
non-classical monocyte | 3 studies | 19% ± 4% | |
smooth muscle cell | 3 studies | 20% ± 3% | |
erythroblast | 3 studies | 27% ± 10% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
macrophage | 3 studies | 20% ± 3% | |
GABAergic neuron | 3 studies | 23% ± 3% | |
glutamatergic neuron | 3 studies | 25% ± 5% | |
dendritic cell | 3 studies | 28% ± 5% | |
intestinal crypt stem cell | 3 studies | 17% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 22% ± 4% | |
astrocyte | 3 studies | 24% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 2670.31 | 180 / 180 | 100% | 13.68 | 430 / 430 |
pancreas | 100% | 1937.69 | 328 / 328 | 100% | 13.16 | 178 / 178 |
prostate | 100% | 2545.71 | 245 / 245 | 100% | 16.16 | 502 / 502 |
uterus | 100% | 2494.60 | 170 / 170 | 100% | 17.47 | 459 / 459 |
skin | 100% | 2465.24 | 1808 / 1809 | 100% | 17.61 | 472 / 472 |
kidney | 100% | 2021.98 | 89 / 89 | 100% | 12.16 | 900 / 901 |
thymus | 100% | 2607.74 | 653 / 653 | 100% | 20.13 | 604 / 605 |
bladder | 100% | 2601.71 | 21 / 21 | 100% | 17.55 | 503 / 504 |
brain | 100% | 1554.69 | 2633 / 2642 | 100% | 14.91 | 705 / 705 |
lung | 100% | 2069.27 | 577 / 578 | 100% | 14.69 | 1153 / 1155 |
breast | 100% | 2285.98 | 459 / 459 | 100% | 14.11 | 1114 / 1118 |
intestine | 100% | 2526.42 | 966 / 966 | 99% | 12.69 | 524 / 527 |
esophagus | 100% | 2180.72 | 1445 / 1445 | 99% | 9.87 | 181 / 183 |
liver | 100% | 1373.60 | 226 / 226 | 98% | 8.47 | 399 / 406 |
stomach | 100% | 1874.89 | 359 / 359 | 98% | 10.80 | 281 / 286 |
adrenal gland | 100% | 1895.00 | 258 / 258 | 98% | 14.16 | 225 / 230 |
adipose | 100% | 1954.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.41 | 29 / 29 |
spleen | 100% | 2752.69 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.15 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.23 | 1 / 1 |
blood vessel | 100% | 2363.59 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1627.35 | 801 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 12.08 | 79 / 80 |
heart | 98% | 1400.08 | 844 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 1681.79 | 876 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045070 | Biological process | positive regulation of viral genome replication |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0006457 | Biological process | protein folding |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0000413 | Biological process | protein peptidyl-prolyl isomerization |
GO_0005576 | Cellular component | extracellular region |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0071007 | Cellular component | U2-type catalytic step 2 spliceosome |
GO_0034774 | Cellular component | secretory granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005634 | Cellular component | nucleus |
GO_0008143 | Molecular function | poly(A) binding |
GO_0003755 | Molecular function | peptidyl-prolyl cis-trans isomerase activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0016018 | Molecular function | cyclosporin A binding |
Gene name | PPIE |
Protein name | Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8) Peptidyl-prolyl cis-trans isomerase E (PPIase E) (EC 5.2.1.8) (Cyclophilin E) (Cyclophilin-33) (Rotamase E) Peptidylprolyl isomerase E |
Synonyms | CYP33 |
Description | FUNCTION: Involved in pre-mRNA splicing as component of the spliceosome . Combines RNA-binding and PPIase activities . Binds mRNA and has a preference for single-stranded RNA molecules with poly-A and poly-U stretches, suggesting it binds to the poly(A)-region in the 3'-UTR of mRNA molecules . Catalyzes the cis-trans isomerization of proline imidic peptide bonds in proteins . Inhibits KMT2A activity; this requires proline isomerase activity . . FUNCTION: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. . FUNCTION: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. . |
Accessions | E9PK21 H0YE31 ENST00000372835.9 ENST00000470213.5 ENST00000497370.5 E9PEQ6 E9PIB0 H0YCV4 E9PMH0 ENST00000474804.5 ENST00000470018.5 ENST00000324379.10 [Q9UNP9-1] ENST00000495526.5 ENST00000475350.5 ENST00000356511.6 [Q9UNP9-2] ENST00000372830.5 [Q9UNP9-3] E9PKY5 Q9UNP9 |